Become A Featured Company

NASDAQ-listed Enveric Acquires MagicMed to Bring Psychedelics Derivatives to Market

Ryan Allway

May 25th, 2021

App, Exclusive, Psychedelics, Top Story

 Enveric Biosciences (NASDAQ: ENVB), best-known for its pipeline of naturally occurring cannabinoid compounds, recently entered into a definitive agreement to acquire MagicMed Industries, a private biotechnology company focused on building a library of novel derivative psychedelic molecules with applications across multiple indications.

The transaction broadens Enveric Bioscience’s focus into psychedelics and complements its existing pipeline of naturally occurring cannabinoid compounds. In addition to its current focus on oncology, the move will enable the company to move into the clinic with novel therapies across oncology and central nervous system disorders, such as PTSD.

Upon closing of the transaction, MagicMed’s Dr. Joseph Tucker will be appointed Chief Executive Officer of Enveric Biosciences. Dr. Tucker is a seasoned executive that has built several publicly traded companies, including Stem Cell Therapeutics and Epimeron Inc., which became a part of Willow Biosciences Inc. during its original formation.

Drug Discovery + Clinical Stage Biotech

Enveric Biosciences has traditionally focused on identifying and developing undervalued, under-researched and naturally occurring cannabinoid compounds in partnership with leading clinics. With existing anecdotal evidence and strong patient and clinician interest, these compounds were focused on oncological conditions, such as GBM, and palliative care.

MagicMed has focused on creating a library of molecular derivatives of psilocybin and DMT, among other psychedelics. By combining non-patentable naturally occurring molecules with other building blocks, the company aims to create derivative molecules that are both patentable and customized to target specific diseases or conditions.

With the acquisition of MagicMed, Enveric Biosciences gains access to this robust derivatives library—the Psybrary™—consisting of a collection of novel psychedelic-derivative drug candidates, manufacturing methods, pharmacological data and patent filings. MagicMed has already filed 14 patent applications covering over 125 million individual molecules.

The acquisition combines this sprawling psychedelic derivative library with Enveric Bioscience’s experienced clinical team to bring its pipeline of molecules through the clinic to help serve millions of patients suffering from mental health conditions around the world. The combined platform targets a massive total addressable market underserved by today’s drugs.

What’s Next for Investors?

MagicMed’s acquisition by Enveric Biosciences represents a major leap forward for both businesses. As a NASDAQ-listed company, Enveric Biosciences has significant liquidity and capital market resources, setting it apart from many other psychedelic-focused companies that trade on junior stock exchanges, like the OTC Markets.

“Our proposed acquisition of MagicMed underscores the core fundamental mission of Enveric to form a drug discovery and clinical-stage biotechnology company with a focus on bringing forward nature-originated therapies to improve the standard of care and serve unmet needs in oncology and CNS indications,” said David Johnson, CEO of Enveric Biosciences.

With more than 200+ distinct psilocybin-derivative drug candidates synthesized at MagicMed’s state-of-the-art R&D facility in Calgary, the combined company has a psychedelics portfolio that’s ripe for near-term clinical development along with an experienced clinical development team that’s well-equipped to drive long-term shareholder value.

For more information, visit the company’s website or download their investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading